A Preliminary Study on the Reduction of PCI Associated Myocardial Infarction by Salvianolate

OBJECTIVE To observe the effect and mechanism of salvianolate on percutaneous coronary intervention (PCI) related myocardial infarction. METHODS The patients with angina pectoris were divided into control group and salvianolate group. Both groups were given standard angina pectoris treatment. The patients in salvianolate group received infusion of salvianolate before PCI and perioperative. Cardiac troponin I (cTnI), soluble thrombomodulin (sTM), von willebrand factor (vWF) were measured on the first day after admission and 24 h after PCI. The baseline data of the two groups patients as well as the clinical events 6 months after PCI and the treatment of cardiovascular events were observed. RESULTS The levels of sTM, vWF and cTnI in both group increased after PCI. The level of sTM and vWF in the salvianolate group after PCI was less than control group, the difference was statistically significant (P<0.05). The incidence of PCI-related myocardial infarction in salvianolate group was lower than that in control group, the difference was statistically significant (P<0.05). The recurrence rate of angina pectoris in salvianolate group was lower than that in control group 6 months after operation (P<0.05). There was no significant difference in coronary angiography between the two groups. There were no adverse cardiovascular events such as target vessel revascularization, non-fatal myocardial infarction, stent thrombosis, cardiogenic shock, or sudden cardiovascular death in both two groups. CONCLUSION Salvianolate may reduce PCI-induced myocardial infarction and improve prognosis of patients by decreasing vascular endothelial injury during PCI.